ORTHOPEDIATRICS CORP KIDS
OrthoPediatrics Corp. (the "Company") is a Delaware corporation, headquartered in Warsaw, Indiana, and organized in November 2007. The Company's Common Stock is traded on the Nasdaq Global Market under the symbol KIDS. OrthoPediatrics Corp. is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments and specialized braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. Initially organized as an Indiana limited liability company on August 31, 2006, OrthoPediatrics Corp. was converted to a Delaware corporation on November 30, 2007. We sell our specialized products, including PediLoc®, PediPlates®, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc® Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSETM Spine, BandLocTM, Pediatric Nailing Platform | Femur, Devise Rail, Orthex®, The Fassier-Duval Telescopic Intramedullary System®, SLIMTM Nail, The GAP NailTM, The Free Gliding SCFE Screw SystemTM, GIRO™ Growth Modulation System, PNP Tibia System, ApiFix® Mid-C System, Mitchell Ponseti®, VerteGlideTM, and Boston Brace 3D® specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation while our orthopedic bracing products are typically manufactured in-house. We also operate multiple orthotic and prosthetic ("O&P") clinics delivering leading pediatric non-surgical O&P treatment.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- U.S.
- International
| Region | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| U.S. | $186.4M | $161.2M | $111.0M |
| International | $49.9M | $43.6M | $37.7M |
As the company reported it, from the “BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $236.3M | $204.7M | $148.7M | $122.3M | $98.0M | $71.1M | $72.6M | $57.6M | $45.6M | $37.3M |
| Cost of revenue | $63.7M | $56.1M | $37.5M | $31.6M | $24.6M | $16.0M | $17.9M | $14.9M | $11.2M | $10.9M |
| Gross profit | $172.7M | $148.6M | $111.3M | $90.7M | $73.4M | $55.0M | $54.6M | $42.7M | $34.5M | $26.4M |
| R&D | $9.1M | $11.0M | $10.9M | $8.5M | $5.5M | $5.3M | $5.7M | $4.7M | $3.4M | $2.2M |
| SG&A | $119.8M | $102.8M | $73.3M | $57.9M | $46.1M | $38.3M | $26.7M | $20.9M | $17.0M | $11.6M |
| Total operating expenses | $211.9M | $183.6M | $138.0M | $116.1M | $91.4M | $81.8M | $63.7M | $52.2M | $40.9M | $32.5M |
| Operating income | -$39.2M | -$35.0M | -$26.8M | -$25.4M | -$18.0M | -$26.8M | -$9.1M | -$9.6M | -$6.5M | -$6.1M |
| Interest expense | $6.0M | $2.6M | $198.0K | $2.4M | $2.2M | $3.4M | $3.5M | $2.3M | $2.5M | $1.5M |
| Pre-tax income | -$39.2M | -$41.9M | -$21.3M | -$3.7M | -$17.4M | -$33.7M | -$12.7M | -$12.0M | -$8.9M | -$6.6M |
| Income tax | $460.0K | $4.1M | $338.0K | $4.9M | $1.1M | $723.0K | $0 | $0 | $0 | $0 |
| Net income | -$39.6M | -$37.8M | -$21.0M | $1.3M | -$16.3M | -$32.9M | -$13.7M | -$12.0M | -$8.9M | -$6.6M |
| EPS, basic | -1.69 | -1.64 | -0.92 | 0.06 | -0.84 | -1.82 | -0.94 | — | — | — |
| EPS, diluted | -1.69 | -1.64 | -0.92 | 0.06 | -0.84 | -1.82 | -0.94 | -0.96 | -5.86 | -7.14 |
| Shares, diluted (wtd. avg.) | 23.5M | 23.1M | 22.7M | 20.9M | 19.3M | 18.1M | 14.6M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $19.6M | $43.8M | $33.0M | $10.5M | $9.0M | $30.1M | $72.0M | $60.7M | $42.6M | $1.6M |
| Short-term investments | $41.3M | $25.0M | $49.3M | $109.3M | $45.9M | $55.1M | $0 | — | — | — |
| Receivables | $53.8M | $42.4M | $34.6M | $24.8M | $17.9M | $17.2M | $16.0M | $9.0M | $5.6M | $4.1M |
| Inventory | $133.8M | $117.0M | $105.9M | $78.2M | $57.6M | $53.0M | $38.0M | $25.7M | — | — |
| Total current assets | $256.4M | $237.2M | $226.5M | $226.7M | $133.6M | $158.4M | $128.1M | $97.2M | $69.6M | $20.8M |
| Property, plant and equipment | $49.6M | $50.6M | $41.0M | $34.3M | $28.5M | $27.2M | $21.3M | $12.8M | $10.4M | $8.6M |
| Goodwill | $109.3M | $93.8M | $83.7M | $86.8M | $72.3M | $70.5M | $13.8M | $0 | — | — |
| Other intangibles | $64.8M | $64.4M | $69.3M | $65.0M | $55.5M | $50.3M | $14.5M | $1.9M | $2.3M | $1.3M |
| Total assets | $508.6M | $473.2M | $438.7M | $427.7M | $304.3M | $320.4M | $182.2M | $112.1M | $82.3M | $30.7M |
| Accounts payable | $18.8M | $8.9M | $12.6M | $11.2M | $9.3M | $10.0M | $6.5M | $4.0M | $5.5M | $3.5M |
| Short-term debt | $1.9M | $897.0K | $152.0K | $144.0K | $137.0K | $131.0K | $124.0K | $118.0K | $113.0K | $107.0K |
| Total current liabilities | $46.2M | $34.0M | $41.7M | $30.9M | $29.7M | $35.0M | $13.7M | $9.2M | $9.5M | $7.3M |
| Long-term debt | $99.8M | $73.0M | $9.9M | $763.0K | $907.0K | $1.0M | $26.1M | $21.2M | $25.3M | $17.4M |
| Total liabilities | $162.0M | $118.6M | $61.7M | $49.1M | $78.9M | $85.6M | $39.8M | $30.4M | $34.8M | $24.7M |
| Retained earnings | -$275.2M | -$235.6M | -$197.7M | -$176.8M | -$178.0M | -$161.8M | -$128.8M | -$115.1M | -$103.1M | -$78.1M |
| Total equity | $346.6M | $354.6M | $377.0M | $378.6M | $225.4M | $234.8M | $142.4M | $81.7M | $47.5M | -$65.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.9M | -$27.0M | -$27.0M | -$21.8M | -$13.1M | -$18.5M | -$17.8M | -$15.6M | -$7.2M | -$1.1M |
| Depreciation and amortisation | $21.1M | $19.1M | $17.4M | $13.1M | $10.7M | $8.0M | $4.7M | $2.9M | $2.4M | $1.9M |
| Stock-based compensation | $17.8M | $13.5M | $10.5M | $6.7M | $5.8M | $6.2M | $2.6M | $3.2M | $3.5M | $1.3M |
| Capital expenditure | $11.1M | $14.3M | $16.9M | $10.0M | $8.1M | $10.5M | $11.8M | $5.3M | $5.2M | $4.3M |
| Investing cash flow | -$43.6M | -$13.2M | $41.7M | -$113.4M | -$7.4M | -$69.7M | -$61.9M | -$6.0M | -$6.5M | -$4.8M |
| Financing cash flow | $24.0M | $53.1M | $7.3M | $136.0M | $6.0K | $46.7M | $91.0M | $39.7M | $54.7M | $3.6M |
| Dividends paid | — | — | — | — | — | — | $0 | $0 | $6.0M | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001425450-26-000027.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.3M | $45.6M | $57.6M | $72.6M | $71.1M | $98.0M | $122.3M | $148.7M | $204.7M | $236.3M |
| Gross profit | $26.4M | $34.5M | $42.7M | $54.6M | $55.0M | $73.4M | $90.7M | $111.3M | $148.6M | $172.7M |
| Net income | -$6.6M | -$8.9M | -$12.0M | -$13.7M | -$32.9M | -$16.3M | $1.3M | -$21.0M | -$37.8M | -$39.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |